Bristol Myers Squibb has opened its radiopharmaceutical manufacturing facility in Indianapolis, which played a major role in ...

The Bristol Myers Squibb subsidiary RayzeBio has opened a new 77,000-square-foot facility in Indianapolis, Indiana.

RayzeBio has additional programs for hepatocellular carcinoma. Between $20 million and $25 million is set aside for RYZ801 and RYZ811, advancing both programs in this type of liver cancer through ...

RayzeBio thinks its Ac225 RPT is the next generation in RPT development. The company thinks there are 7000 target patients per year. Rival drug price median is a quarter million dollars.

RayzeBio's $4.1 billion deal to be acquired by Bristol Myers caps a brief but lucrative run as a public company for the radiopharmaceutical firm. RayzeBio went public in September at $18 a share ...

SAN DIEGO--(BUSINESS WIRE)--RayzeBio, Inc., which is discovering and developing a broad pipeline of innovative targeted radiopharmaceutical drugs for cancer, today announced a $108 million Series ...

Rayzebio, Inc. SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- RayzeBio, Inc. (Nasdaq: RYZB), a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor ...

Transaction Brings RayzeBio’s Differentiated Actinium-Based Radiopharmaceutical Platform, Including Rich Pipeline of Multiple Drug Development Programs to Bristol Myers Squibb’s Leading ...

Initiating RayzeBio, Inc. coverage with a Buy rating and common stock price target of $43 based on my risk-adjusted NPV discounted cash flow model, representing a 110% upside.

Rayzebio, Inc. SAN DIEGO, Nov. 06, 2023 (GLOBE NEWSWIRE) -- RayzeBio, Inc. (Nasdaq: RYZB), a biopharmaceutical company developing an innovative radiopharmaceutical pipeline to treat different ...

Neumora and RayzeBio are both casting a line into the market, with each seeking to raise more than $200 million in initial public offerings this fall. Neumora is offering 14,710,000 shares at a ...